DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS Stock

Certificat

DE000ME7WV93

Real-time Bid/Ask 05:48:47 2024-05-29 am EDT
367.51 EUR / 368.67 EUR +0.33% Intraday chart for DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS
Current month+2.18%
1 month+2.25%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-29 366.1 -0.21%
24-05-28 366.9 +0.24%
24-05-27 366 -0.49%
24-05-24 367.8 +3.34%
24-05-23 355.9 -3.41%

Delayed Quote Börse Stuttgart

Last update May 29, 2024 at 02:04 am EDT

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
Issuer Morgan Stanley
WKN ME7WV9
ISINDE000ME7WV93
Date issued 2024-01-30
Cap 400 $
Last trading day 2024-06-21
Maturity 2024-06-21 (24 Days)
Parity 1 : 1
Emission price 356
Emission volume N/A
Payment day 2024-06-28
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 10.48 %
Sideways yield 0.1475 %
Sideways yield pa 2.341 %
Outperformance point 446.8 $
Break even 398.59 €
Highest since issue 368.6
Lowest since issue 347.6
Spread 1.16
Spread %0.31%
Distance Cap 46.88 $
Distance Cap %+10.49%
Max. earning 0.543
Max. earning % 0.1475 %

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9 USD
Average target price
462.8 USD
Spread / Average Target
+3.57%
Consensus